As shown in Figure 4, the level of sema3A protein was expressed lower on CD19+CD25high B cells from SLE patients compared to CD19+CD25high B cells from healthy controls (52.2 ± 5.8% versus 82.6 ± 6.4%, P < 0.0001, respectively (MFI: 2.68 ± 0.09 versus 4.27 ± 0.47, P = 0.019). This evidence concerns the gene SEMA3A and systemic lupus erythematosus.